Trial Profile
Pilot Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2023
Price :
$35
*
At a glance
- Drugs Dronabinol (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms THC-AD
- 03 May 2023 Planned End Date changed from 1 May 2023 to 31 May 2024.
- 03 May 2023 Planned primary completion date changed from 1 May 2023 to 31 May 2024.
- 04 Aug 2022 Results (n=58) assessing safety and efficacy of dronabinol adjunctive treatment of agitation in alzheimers disease, presented at the Alzheimer's Association International Conference 2022.